Mumbai: Drug maker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from the United States Food and Drug Administration (USFDA).
The product is a generic version of Zonegran (Zonisamide) Capsules of Sunovion Pharmaceuticals Inc.
Zonisamide Capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.
The product will be commercialized from Unichem's Goa Plant.
Read also: Unichem Labs gets USFDA nod for Atenolol, Chlorthalidone Tablets
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company.
It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Labs osteoarthritis drug Celecoxib gets USFDA okay
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!